Manchester, UK, 11 September 2010 - F2G Limited, the UK based antifungal drug discovery
and development company, today announced the appointment of Dr Michael R. Hodges to the
Company’s Board of Directors.
Michael R Hodges, M.D., BSc., MRCP (UK) has 20 years of biopharmaceutical development
experience and has worked in both biotechnology and large pharmaceutical companies. Whilst
at Pfizer Inc. Dr. Hodges was the development team leader for Vfend™, the gold standard
therapy for invasive aspergillosis, as well as working on the Eraxis™ and Diflucan™ antifungal
programs. In addition Dr. Hodges worked on the Zithromax™ and HIV portfolio development
Prior to joining industry at Pfizer Inc. in 1990, Dr. Hodges practiced internal medicine in London,
UK. 1989-90 he held an appointment through the Medical Research Council (UK), at St Thomas’
Hospital, London, HIV clinical trials unit. From 1992 to 2001 he held honoree positions with East
Kent Hospitals University NHS Foundation Trust.
Shane Kelly, Chief Executive of F2G commented “It is with great pleasure that we announce that
Michael Hodges has accepted our invitation to join the Board. His track record in the successful
development and transition of antifungals to market will be invaluable as F2G continues to
advance its portfolio of antifungal agents.”
Dr Richard White, Chairman of the Board added “We are delighted to welcome Michael to the
Board. His knowledge and experience in the antifungal sector will be a considerable asset to
F2G and I look forward to working with him towards the further development of F2G’s antifungal
Commenting on his appointment, Dr Michael Hodges said “I am delighted to be joining the
Board of Directors, especially at such an exciting time for the company as they move their series
of novel antifungal drug candidates into the clinic”.
Registered office: Lankro Way, Eccles, Manchester M30 0BH
tel: 0161 785 1270; fax: 0161 785 1273; e-mail: email@example.com; website: www.f2g.com
Company registration number: 03578625; VAT number: GB 712680645 ®
About F2G Ltd:
Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and
clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk
patient populations. The antifungal market is currently estimated at over 6 billion dollars
annually and is growing steadily year on year. Market growth is expected to increase with the
emergence of new clinical indications in allergies and asthma.
The company has impressive internal capabilities, employing a core team of scientists with a
unique understanding of the antifungal arena, supported by an experienced management team.
F2G operates a flexible business model, building value through the development of a balanced
portfolio of antifungal assets across multiple validated TPPs.
For more information visit www.f2g.com
Chief Executive Officer, F2G Ltd
Tel: (+44) 0161 785 1271 Fax: (+44) 0161 785 1273